New aspects of the blood coagulation cascade, anticoagulants and vein thrombosis in Asia

Annals of the Academy of Medicine Singapore

Volumn 31, Issue 6, 2002, Pages 685-696

  Gallus, A S ^a   Lee, L H ^b   Coghlan, D W ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Haemostasis; Novel antithrombotics; Pulmonary embolism; Thrombophilia; Thrombosis prevention; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 9; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBIN;

ASIA; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; CLINICAL STUDY; DISEASE PREDISPOSITION; DRUG EFFICACY; EUROPE; GENETIC POLYMORPHISM; HEMOSTASIS; HUMAN; JOINT SURGERY; LANGUAGE; LUNG EMBOLISM; MEDICAL ASSESSMENT; NEGATIVE FEEDBACK; PHYSIOLOGY; PUBLICATION; REVIEW; RISK FACTOR; STROKE; THROMBIN TIME; THROMBOEMBOLISM; THROMBOPHILIA; TISSUE PRESERVATION; VEIN THROMBOSIS;

EID: 0036879837     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Colman R W, Hirsh J, Marder V J, Clowes A W. Blood coagulation factors: their complementary DNA's, genes and expressions. In: Colman R W, Hirsh J, Marder V J, Clowes A W, George J N, editors. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001:17-57.
2. Esmon C T. Protein C, protein S, and thrombomodulin. In: Colman R W, Hirsh J, Marder V J, Clowes A W, George J N, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:335-53.
3. Hirsh J, Colman R W, Marder V J, George J N, Clowes A W. Overview of thrombosis and its treatment. In: Colman R W, Hirsh J, Marder V J, Clowes A W, George J N, editors. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:1071-84.
4. Rosenberg R D, Edelberg J M, Zhang L. The heparin/antithrombin system: a natural anticoagulant mechanism. In: Colman R W, Hirsh J, Marder V J, Clowes A W, George J N, editors. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:711-31.
5. Reiner A P, Siscovick D S, Rosendaal F R. Hemostatic risk factors and arterial thrombotic disease. Thrombos Haemostas 2001; 85:584-95.
6. Marder V J, Matei D E. Hereditary and acquired thrombophilic syndromes. In: Colman R W, Hirsh J, Marder V J, Clowes A W, George J N, editors. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:1243-75.
7. Emmerich J, Rosendaal F R, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86:809-16.
8. Townend J, O'Sullivan J, Wilde J T. Hyperhomocysteinemia and vascular disease. Blood Rev 1998; 12:23-34.
9. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81:165-76.
10. Kyrle P A, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343:462.
11. van Hylckama Vlieg A, van der Linden I K, Bertina R M, Rosendaal F R. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95:3678-82.
12. Meijers J C M, Tekelenburg W L H, Bouma B N, Bertina R M, Rosendaal F R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000:342:696-701.
13. van Tilburg N H, Rosendaal F R, Bertina R M. Thrombin activable fibrinolysis inhibitor and the risk of deep vein thrombosis. Blood 2000; 95:2855-9.
14. Walker I D. Thrombophilia in pregnancy. J Clin Pathol 2000; 53:573-80.
15. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002; 101:6-14.
16. Roberts D, Schwartz R S. Clotting and hemorrhage in the placenta-a delicate balance. N Engl J Med 2002; 347:57-9.
17. Walker I D. Prothrombotic genotypes and pre-eclampsia. Thromb Haemost 2002; 87:777-8.
18. Morrison E R, Miedzybrodzka Z H, Campbell D M, Haites N E, Wilson B J, Watson M S, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: Results from a large population-based study and systematic review. Thromb Haemost 2002; 87:779-85.
19. Infante-Rivard C, Rivard G-E, Yotov W V, Glenin E, Guiguet M, Weinberg C, et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002; 347:19-25.
20. White R H, Zhou H, Romano P S. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128:737-40.
21. Klatsky A L, Armstrong M A, Poggi J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am J Cardiol 2000; 85:1334-7.
22. Rees D C, Chapman N H, Webster M T, Guerreiro J F, Rochette J, Clegg J B. Born to clot: the European burden. Br J Haematol 1999; 105:564-6.
23. Shen M-C, Lin J-S, Tsay W. High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. Thromb Res 1997; 87:377-85.
24. Lin J S, Shen M C, Tsay W. The mutation at position 20210 in the 3′-untranslated region of the prothrombin gene is extremely rare in Taiwanese Chinese patients with venous thrombosis. Thromb Haemost 1998; 80:343.
25. Lim L C, Tan H H, Lee L H, Tien S L, Abdul Ghafar A. Activated protein C resistance: A study among 60 thromboembolic patients in the Singapore population. Ann Acad Med Singapore 1999; 28:252-5.
26. Liu H W, Kwong Y L, Bourke C, Lam C K, Lie A K W, Wei D, et al. High incidence of thrombophilia detected in Chinese patients with venous thrombosis. Thromb Haemost 1994; 71:416-9.
27. Hwang W S. The rarity of pulmonary thromboembolism in Asians. Singapore Med J 1968; 9:276-9.
28. Lau G. Pulmonary thromboembolism is not uncommon-results and implications of a five-year study of 116 necropsies. Ann Acad Med Singapore 1995; 24:356-65.
29. Dickens P, Knight B H, Ip P, Fung W S. Fatal pulmonary embolism: a comparative study of autopsy incidence in Hong Kong and Cardiff, Wales. Forensic Sci Int 1997; 90:171-4.
30. Chan C W, Hoaglund F T. Pulmonary thromboembolism and venous thrombosis in the Chinese. Clin Orthop Rel Res 1980; 150:253-60.
31. Chau K Y, Yuen S T, Wong M P. Clinicopathological pattern of pulmonary thromboembolism in Chinese autopsy patients: comparison with Caucasian series. Pathology 1997; 29:263-6.
32. Teo C E S. A study of coroner's cases from hospitals: a comparison of autopsy and clinical diagnosis. Ann Acad Med Singapore 1993; 22:3-7.
33. Chau K Y, Yuen S T, Ng T H K, Ng W F. An autopsy study of pulmonary thromboembolism in Hong Kong Chinese. Pathology 1991; 23:181-4.
34. Nakamura M, Fujioka H, Yamada N, Sakuma M, Okada O, Nakanishi N. et al. Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol 2001; 24:132-8.
35. Peng Y Y, Jeng J S, Shen M-C, Tsay W, Wang B-S, Lin W-H, et al. Aetiologies and prognosis of Chinese patients with deep vein thrombosis of the lower extremities. Q J Med 1998; 91:681-6.
36. Woo K S, Mak G Y K, Sun J J, Woo J L F, Metreweli C, Vallance-Owen J. The incidence and clinical pattern of deep vein thrombosis in the Chinese in Hong Kong. Singapore Med J 1988; 29:357-9.
37. Liam C K, Ng S C. A review of patients with deep vein thrombosis diagnosed at University Hospital, Kuala Lumpur. Ann Acad Med Singapore 1990; 19:837-40.
38. Kueh Y K, Wang T L, Teo C P, Tan Y O. Acute deep vein thrombosis in hospital practice. Ann Acad Med Singapore 1992; 21:345-8.
39. Lee L H, Gu K, Heng D. Deep vein thrombosis is not rare in Asia-the Singapore General Hospital experience. Ann Acad Med Singapore 2002; 31.
40. Anderson F A, Wheeler B, Goldberg R J, Hosmer D W, Patwardhan N A, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151:933-8.
41. Chan L Y, Tan W H, Lau T K. Venous thromboembolism in pregnant Chinese women. Obstet Gynecol 2001; 98:471-5.
42. Kum C K, Sim E K, Ngoi S S. Deep vein thrombosis complicating colorectal surgery in the Chinese in Singapore. Ann Acad Med Singapore 1993; 22:895-7.
43. Tay B H, Masbah O, Razak M, Ruslan G N. Total hip arthroplasty in Malaysia - the Universiti Kebangsaan Malaysia and Hospital Kuala Lumpur experience. Med J Malaysia 2000; 55:74-85.
44. Tsutsumi K, Udagawa H, Kajiyama Y, Kinoshita Y, Ueno M, Nakamura T, et al. Pulmonary thromboembolism after surgery for esophageal cancer: its features and prophylaxis. Surg Today 2000; 30:416-20.
45. Geerts W H, Heit J A, Clagett G P, Pineo G F, Colwell C W, Anderson F A, et al. Prevention of venous thromboembolism. Chest 2001; 119:132S-75S.
46. Yoo M C, Kang C S, Kim Y H, Kim S K. A prospective randomized study on the use of nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement. Int Orthop 1997; 21:399-402.
47. Kim Y H, Choi I Y, Park M R, Park T S, Cho J L. Prophylaxis for deep vein thrombosis with aspirin or low molecular weight dextran in Korean patients undergoing total hip replacement. A randomized controlled trial. Int Orthop 1998; 22:6-10.
48. Fujita S, Hirota S, Oda T, Kato Y, Tsukamoto Y, Fuji T. Deep venous thrombosis after total hip or total knee arthroplasty in Japan. Clin Orthop Rel Res 2000; 375:168-74.
49. Dhillon K S, Askander A, Doraismy S. Postoperative deep-vein thrombosis in Asian patients is not a rarity: a prospective study of 88 patients with no prophylaxis. J Bone Joint Surg 1996; 78-B:427-30.
50. Wang C J, Wang J W, Chen L M, Chen H S, Yang B Y, Cheng S M. Deep vein thrombosis after total knee arthroplasty. J Formos Med Assoc 2000; 99:848-53.
51. Ruban P, Yeo S J, Seow K H, Tan S K, Ng S C K. Deep vein thrombosis after total knee replacement. Ann Acad Med Singapore 2000; 29:428-33.
52. Mok C K, Hoaglund F T, Rogoff S M, Chow S P, Ma A, Yau A C M C. The incidence of deep vein thrombosis in Hong Kong Chinese after hip surgery for fracture of the proximal femur. Br J Surg 1979; 66:640-2.
53. Kew J, Lee Y L, Davey I C, Ho S Y, Fung K C, Metreweli C. Deep vein thrombosis in elderly Hong Kong Chinese with hip fractures detected with compression ultrasound and Doppler imaging: incidence and effects of low molecular weight heparin. Arch Orthop Trauma Surg 1999; 119:156-8.
54. Lee H M, Suk K S, Moon S H, Kim D J, Wang J M, Kim N H. Deep vein thrombosis after major spinal surgery: incidence in an East Asian population. Spine 2000; 25:1827-30.
55. Cunningham I G E, Yong N K. The incidence of postoperative deep vein thrombosis in Malaysia. Br J Surg 1974; 61:482-3.
56. Nandi P, Wong K P, Wei W I, Ngan H, Ong G B. Incidence of postoperative deep vein thrombosis in Hong Kong Chinese. Br J Surg 1980; 67:251-3.
57. Lee F Y, Chu W, Chan R, Leung Y F, Ng S M, Lai P B, et al. Incidence of deep vein thrombosis after colorectal surgery in a Chinese population. Aust N Z J Surg 2001; 71:637-40.
58. Inada K, Shirai N, Matsumoto K, Hirose M. Postoperative deep vein thrombosis in Japan. Am J Surg 1983; 145:775-9.
59. Ho Y H, Seow-Choen F, Leong A, Eu K W, Nyam D, Teoh M K. Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients. Dis Colon Rectum 1999; 42:196-202.
60. Chumnijarakij T, Poshyachinda V. Postoperative thrombosis in Thai women. Lancet 1975; 1:1357-8.
61. Tso S C, Wong V, Chan V, Chan T K, Chan H K, Ma H K, et al. Deep vein thrombosis and changes in coagulation and fibrinolysis after gynecological operations in Chinese: effect of oral contraceptives and malignant disease. Br J Haematol 1980; 46:603-12.
62. Tso S C. Deep vein thrombosis after strokes in Chinese. Aust N Z J Med 1980; 10:513-4.
63. Arocas V, Bock S C, Raja S, Olson S T, Bjork I. Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J Biol Chem 2001; 276:43809-17.
64. Petitou M, Herault J P, Bernat A, Driiguez P-A, Duchaussoy P, Lormeau J-C, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999; 398:417-22.
65. Whisstock J C, Pike R N. Jin L, Skinner R, Pei X Y, Carrell R W, et al. Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparindagger. J Mol Biol 2000; 301:1287-305.
66. Hirsh J, Warkentin T, Shoughnessy S G, Anand S S, Halperin J S, Raschke R, et al. Heparin and low molecular weight heparins. Mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(Suppl):64S-94S.
67. Walenga J M, Bara L, Petitou M, Samama M M, Fareed J, Choay J. The inhibition of the generation of thrombin and the antithrombotic activity of a pentasaccharide with sole anti-factor Xa activity. Thromb Res 1988; 51:23-33.
68. Beguin S, Choay J, Hemker H C. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989; 61:397-401.
69. Herbert J M, Petitou M, Lormeau J C, Cariou R, Necciari J, Magnani H N, et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15:1-26.
70. Elalamy I, Lecrubier C, Potevin F, Abdelouahed M, Bara L, Marie J P, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995; 74:1385-6.
71. Amiral J, Lormeau J C, Marfaing-Kolka A, Vissac A M, Wolf M, Boyer-Neumann C, et al. Absence of cross-reactivity of SR 90107A/ORG 31540 pentsasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8:114-7.
72. Walenga J M, Jeske W P, Bara L, Samama M M, Fareed J. Biochemical and pharmacological rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86:1-36.
73. Ahmad S, Jeske W P, Walenga J M, Hoppensteadt D A, Wood J J, Herbert J M, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 1999; 5:259-66.
74. Herbert J M, Herault J P, Bernat A, van Amsterdam R G, Lormeau J C, Petitou M, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91:4179-205.
75. Petitou M, van Boeckel C. Heparin: from the original "soup" to well-designed heparin mimetics. Pure Appl Chem 1997; 69:1839-46.
76. Jenny N S, Mann K G. Thrombin. In: Colman R W, Hirsh J, Marder V J, Clowes A W, George J N, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:171-89.
77. Weitz G, Hirsh J. New anticoagulant drugs. Chest 2001; 119(Suppl):95S-107S.
78. Cairns J A, Theroux P, Lewis H D, Ezekowitz M, Meade T W. Antithrombotic agents in coronary artery disease. Chest 2001; 119(Suppl):228S-52S.
79. Eriksson B I, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, et al. Prevention of thromboembolism with use of recombinant hirudin. Result of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg 1997; 79-A:326-33.
80. Eriksson B I, Wille-Jorgensen P, Kalebo P, Mouret P, Rosenscher N, Bosch P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337:1329-35.
81. Lassen M R, Bauer K A, Eriksson B I, Turpie A G G. Postoperative fondaparinux versus preoperative enoxaparin for the prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359:1721-6.
82. Turpie A G G, Bauer K A, Eriksson B I, Lassen M R. Postoperative fondaparinux versus postoperative enoxaparin for the prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359:1721-6.
83. Eriksson B I, Bauer K A, Lassen M R, Turpie A G G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345:1298-304.
84. Bauer K A, Eriksson B I, Lassen M R, Turpie A G G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345:1305-10.
85. Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet 2002; 359:1710-11.
86. Hull R D, Pineo G F, Stein P D, Mah A, Maclsaac S M, Dahl O E, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: A systematic review. Arch Intern Med 2001; 161:1952-60.
87. Strebel N, Prins M, Agnelli G, Buller H R. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162:1451-6.